RBC Lifts PT on Aerie Pharma (AERI) to $55 Following Roclatan Phase 3 Results

Aerie Pharma (AERI) PT Lifted to $50 at Stifel on Strong Roclatan Results

Stifel analyst Annabel Samimy reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $50.00 (from $40.00) after the company reported unequivocally positive results from its Phase 3 Roclatan MERCURY-1 study. This 90-day primary efficacy readout demonstrated statistically significant IOP-lowering of Roclatan over... More

Aerie Pharma (AERI) PT Raised to $50 at Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and raised his price target on Aerie Pharma (NASDAQ: AERI) to 50.00 (from $44.00) after the company reported "impeccable" Phase 3 results with its combination eye drop Roclatan from a 700-patient+ trial.

Piros commented, "When comparing the... More

Despite Big Move, Aerie Pharma (AERI) Not Getting Credit for Drug Potential - Brean Capital

Brean Capital analyst Difei Yang reiterated a Buy rating and $48 price target on Aerie Pharma (NASDAQ: AERI) after announced top-line efficacy results from its Phase III Mercury 1 clinical trial for Roclatan, a fixed dose combination product designed to treat glaucoma.

Yang said the results, reconfirming... More

Aerie Pharma (AERI) PT Raised to $52 at Needham & Company as Roclatan Knocks It Out of the Park

Needham & Company analyst Serge Belanger reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to $52.00 (from $45.00) after the company reported positive results from MERCURY-1, the first of two ph 3 trials evaluating Roclatan (fixed-dose combo of Rhopressa and latanoprost)... More

Aerie Pharma (AERI) Enters $50M Equity Offering Sales Agreement

Aerie Pharma (NASDAQ: AERI) disclosed the following in a U.S. SEC filing on Thursday:

Item 1.01. Entry into Material Definitive Agreement.

On September 15, 2016, Aerie Pharmaceuticals, Inc. (the Company) entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., acting as agent, pursuant to which the Company may offer and sell, from time to time... More

Aerie Pharma (AERI) Announces Statistically Significant Data from Roclatan Phase 3 Mercury 1 Trial

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening. The study evaluated patients with maximum baseline intraocular pressures (IOPs) ranging from above 20 to below 36 mmHg (millimeters of mercury). The IOP-lowering effect of RoclatanTM was 1 to 3 mmHg greater than... More